SCHEMBL3011844

SCHEMBL3011844

COc1ccc(OC)c(S(=O)(=O)C2CCN(c3nc(Cc4cc(F)cc(Cl)c4)cs3)CC2)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
CCR3 P51677 2/20 0.39
THRB P10828 1/20 0.39
MAPT P10636 3/20 0.39
LMNA P02545 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TP53 P04637 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CCR5 P51681 1/20 0.37
KMT2A Q03164 1/20 0.36
P2RX7 Q99572 4/20 0.36
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
USP2 O75604 1/20 0.35
RECQL P46063 1/20 0.35
GPR6 P46095 1/20 0.35
HTR6 P50406 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006527 0.95 ALDH1A1 (0.43) HSD17B10ALDH1A1HPGDCCR3THRB
SCHEMBL3013857 0.94 ALDH1A1 (0.42) HSD17B10ALDH1A1HPGDCCR3THRB
SCHEMBL3010664 0.94 MAPT (0.40) HSD17B10ALDH1A1HPGDCCR3THRB
SCHEMBL3018015 0.94 MAPT (0.41) ALDH1A1HPGDMAPTLMNATDP1
SCHEMBL3014015 0.91 MAPT (0.38) ALDH1A1MAPTLMNATDP1TP53
SCHEMBL15671702 0.90 MAPT (0.42) ALDH1A1HPGDMAPTLMNATDP1
SCHEMBL3012043 0.89 ALDH1A1 (0.42) HSD17B10ALDH1A1HPGDCCR3THRB
SCHEMBL3015537 0.89 CCR3 (0.41) HSD17B10ALDH1A1HPGDCCR3THRB
SCHEMBL3014972 0.88 MAPT (0.38) HSD17B10ALDH1A1HPGDMAPTLMNA
SCHEMBL3006331 0.88 TP53 (0.40) ALDH1A1HPGDMAPTLMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HSD17B10 2553/4885ALDH1A1 3510/4885HPGD 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.